Genes (Apr 2022)

Comparative Genomic Hybridization to Microarrays in Fetuses with High-Risk Prenatal Indications: Polish Experience with 7400 Pregnancies

  • Katarzyna Kowalczyk,
  • Magdalena Bartnik-Głaska,
  • Marta Smyk,
  • Izabela Plaskota,
  • Joanna Bernaciak,
  • Marta Kędzior,
  • Barbara Wiśniowiecka-Kowalnik,
  • Marta Deperas,
  • Justyna Domaradzka,
  • Alicja Łuszczek,
  • Daria Dutkiewicz,
  • Agata Kozar,
  • Dominika Grad,
  • Magdalena Niemiec,
  • Kamila Ziemkiewicz,
  • Róża Magdziak,
  • Natalia Braun-Walicka,
  • Artur Barczyk,
  • Maciej Geremek,
  • Jennifer Castañeda,
  • Anna Kutkowska-Kaźmierczak,
  • Paweł Własienko,
  • Krystyna Jakubów-Durska,
  • Marzena Dębska,
  • Anna Kucińska-Chahwan,
  • Szymon Kozłowski,
  • Boyana Mikulska,
  • Tadeusz Issat,
  • Tomasz Roszkowski,
  • Agnieszka Nawara-Baran,
  • Agata Runge,
  • Anna Jakubiuk-Tomaszuk,
  • Anna Kruczek,
  • Ewa Kostyk,
  • Grzegorz Pietras,
  • Janusz Limon,
  • Jerzy Zwoliński,
  • Karolina Ochman,
  • Tomasz Szajner,
  • Piotr Węgrzyn,
  • Mirosław Wielgoś,
  • Maria Sąsiadek,
  • Ewa Obersztyn,
  • Beata Anna Nowakowska

DOI
https://doi.org/10.3390/genes13040690
Journal volume & issue
Vol. 13, no. 4
p. 690

Abstract

Read online

The aim of this study was to determine the suitability of the comparative genomic hybridization to microarray (aCGH) technique for prenatal diagnosis, but also to assess the frequency of chromosomal aberrations that may lead to fetal malformations but are not included in the diagnostic report. We present the results of the aCGH in a cohort of 7400 prenatal cases, indicated for invasive testing due to ultrasound abnormalities, high-risk for serum screening, thickened nuchal translucency, family history of genetic abnormalities or congenital abnormalities, and advanced maternal age (AMA). The overall chromosomal aberration detection rate was 27.2% (2010/7400), including 71.2% (1431/2010) of numerical aberrations and 28.8% (579/2010) of structural aberrations. Additionally, the detection rate of clinically significant copy number variants (CNVs) was 6.8% (505/7400) and 0.7% (57/7400) for variants of unknown clinical significance. The detection rate of clinically significant submicroscopic CNVs was 7.9% (334/4204) for fetuses with structural anomalies, 5.4% (18/336) in AMA, 3.1% (22/713) in the group of abnormal serum screening and 6.1% (131/2147) in other indications. Using the aCGH method, it was possible to assess the frequency of pathogenic chromosomal aberrations, of likely pathogenic and of uncertain clinical significance, in the groups of cases with different indications for an invasive test.

Keywords